Experimental disseminated trichosporonosis in mice: tissue distribution and therapy with antifungal agents

Yamamoto, K.; Makimura, Koichi; Sudo, Takako; Shibuya, Kazutoshi; Uchida, Katsuhisa; Yamaguchi, Hideyo

doi:10.1080/02681219780001511

Cited by 14 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are increasing data suggesting that amphotericin B has limited in vitro and in vivo activity against Trichosporon spp., including T. asahii strains (183,193). Amphotericin B MIC values against Trichosporon spp., particularly T. asahii, are generally incompatible with serum levels normally achievable in patients receiving a conventional formulation of this polyene.…”

Section: Antifungal Therapymentioning

confidence: 99%

Current Knowledge of Trichosporon spp. and Trichosporonosis

2011

View full text Add to dashboard Cite

SUMMARY Trichosporon spp. are basidiomycetous yeast-like fungi found widely in nature. Clinical isolates are generally related to superficial infections. However, this fungus has been recognized as an opportunistic agent of invasive infections, mostly in cancer patients and those exposed to invasive medical procedures. It is possible that the ability of Trichosporon strains to form biofilms on implanted devices, the presence of glucuronoxylomannan in their cell walls, and the ability to produce proteases and lipases are all factors likely related to the virulence of this genus and therefore may account for the progress of invasive trichosporonosis. Disseminated trichosporonosis has been increasingly reported worldwide and represents a challenge for both diagnosis and species identification. Phenotypic identification methods are useful for Trichosporon sp. screening, but only molecular methods, such as IGS region sequencing, allow the complete identification of Trichosporon isolates at the species level. Methods for the diagnosis of invasive trichosporonosis include PCR-based methods, Luminex xMAP technology, and, more recently, proteomics. Treating patients with trichosporonosis remains a challenge because of limited data on the in vitro and in vivo activities of antifungal drugs against clinically relevant species of the genus. Despite the mentioned limitations, the use of antifungal regimens containing triazoles appears to be the best therapeutic approach.

show abstract

Section: Antifungal Therapymentioning

confidence: 99%

Current Knowledge of Trichosporon spp. and Trichosporonosis

2011

View full text Add to dashboard Cite

show abstract

“…Skin lesions and positive accessory examination showed no changes. According to the report 6 that combining amphotericin B with fluconazole could prolong the survival time of mice, we initiated the treatment of combined liposomal amphotericin B (Amphotec ® ) with fluconazole. Amphotec increased progressively from 50 mg d −1 , 100 mg d −1 to 150 mg d −1 every 3–5 days, and was maintained at 150 mg d −1 .…”

Section: Therapymentioning

confidence: 99%

“…In 1992, it had been separated from Trichosporon cutaneum and became an independent species 1 . It had been reported in Japan that T. asahii could cause cutaneous infection in leukemia patients, 2,4 lung infection in patients with summer‐type hypersensitivity pneumonitis, 5 and experimental disseminated trichosporonosis in mouse 6 . We treated a patient with disseminated infection caused by T. asahii in 2000.…”

Section: Introductionmentioning

confidence: 99%

Disseminated trichosporonosis in China

Wang

Song

et al. 2003

Mycoses

View full text Add to dashboard Cite

A 20-year-old female patient presented with erythematous plaques on the nose which were progressively spreading to the trunk and the extremities, sometimes with erosions and scars. The patient was misdiagnosed as having seborrhoeic dermatitis and subacute cutaneous lupus erythematosus. The histopathological biopsy revealed mycotic infectious granuloma. Samples taken from skin lesions and other locations grew Trichosporon asahii in cultures. The identification was confirmed by molecular biological methods. The patient was treated successfully with liposomal amphotericin B in combination with fluconazole orally.

show abstract

“…Previous to our study, there were few studies reporting animal models for Trichosporonosis. [33][34][35][36][37][38][39] We extended these studies by developing Galleria mellonella and murine models of Trichosporon infection and used them to further assess the efficacy of the 3 antifungal therapies, AMB, FLC, and VRC, in vivo. The combination of these in vitro and in vivo assays represents the framework for use in large scale investigations that study the molecular determinants of virulence and antifungal resistance.…”

Section: Introductionmentioning

confidence: 99%

The development of animal infection models and antifungal efficacy assays against clinical isolates ofTrichosporon asahii,T. asteroidesandT. inkin

et al. 2015

View full text Add to dashboard Cite

The present study developed Galleria mellonella and murine infection models for the study of Trichosporon infections. The utility of the developed animal models was demonstrated through the assessment of virulence and antifungal efficacy for 7 clinical isolates of Trichosporon asahii, T. asteroides and T. inkin. The susceptibility of the Trichosporon isolates to several common antifungal drugs was tested in vitro using the broth microdilution and the Etest methods. The E-test method depicted a lower minimal inhibitory concentration (MIC) for amphotericin and a slightly higher MIC for caspofungin, while MICs observed for the azoles were different but comparable between both methods. All three Trichosporon species established infection in both the G. mellonella and immunosuppressed murine models. Species and strain dependent differences were observed in both the G. mellonella and murine models. T. asahii was demonstrated to be more virulent than the other 2 species in both animal hosts. Significant differences in virulence were observed between strains for T. asteroides in the murine model. In both animal models, fluconazole and voriconazole were able to improve the survival of the animals compared to the untreated control groups infected with any of the 3 Trichosporon species. In G. mellonella, amphotericin was not able to reduce mortality in any of the 3 species. In contrast, amphotericin was able to reduce murine mortality in the T. asahii or T. inkin models, respectively. Hence, the developed animal infection models can be directly applicable to the future deeper investigation of the molecular determinants of Trichosporon virulence and antifungal resistance.

show abstract

Experimental disseminated trichosporonosis in mice: tissue distribution and therapy with antifungal agents

Cited by 14 publications

References 26 publications

Current Knowledge of Trichosporon spp. and Trichosporonosis

Current Knowledge of Trichosporon spp. and Trichosporonosis

Disseminated trichosporonosis in China

The development of animal infection models and antifungal efficacy assays against clinical isolates ofTrichosporon asahii,T. asteroidesandT. inkin

Contact Info

Product

Resources

About